Lanzhou Univ. BRD4 compound X9

Lanzhou Univ. BRD4 compound X9: sourced facts only. name: "The representative compound X9 showed potent BRD4 inhibitory activity (with IC50 = 82.3 nM), and preferable antiproliferative activity against HepG2 cells (with IC50 = 1.13 ± 0.07 μM), as well as less toxicity against GES-1 cells (with IC50 = 57.24 ± 5.46 μM)." [PMID:36599264]; target: "The representative compound X9 showed potent BRD4 inhibitory activity (with IC50 = 82.3 nM), and preferable antiproliferative activity against HepG2 cells (with IC50 = 1.13 ± 0.07 μM), as well as less toxicity against GES-1 cells (with IC50 = 57.24 ± 5.46 μM)." [PMID:36599264]; developer: "School of Pharmacy & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China." [PMID:36599264]; stage: "Furthermore, compound X9 dose-dependently inhibited colony formation and blocked the migration of HepG2 cells by down-regulating the expression of Snail and MMP-9 while up-regulating the E-cadherin and Occludin." [PMID:36599264]